Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
about
Targeting Cell Survival Proteins for Cancer Cell DeathTargeting the Bcl-2 family for cancer therapySolution structure of human BCL-w: modulation of ligand binding by the C-terminal helixMitochondrial apoptosis and BH3 mimeticsEDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.BCL2 family of apoptosis-related genes: functions and clinical implications in cancer.Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosisA major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population.How to unleash mitochondrial apoptotic blockades to kill cancers?Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.Expression of factors involved in apoptosis and cell survival is correlated with enzymes synthesizing lysophosphatidic acid and its receptors in granulosa cells originating from different types of bovine ovarian follicles.Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die.Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression.
P2860
Q26765447-DAFFAA78-A3B3-44BB-9F0E-9D33392C2723Q26866936-2458A7C5-9047-41D2-89A9-F11591671341Q27640755-837A905A-D6EA-47C9-8F1F-4CD1DD49B84CQ28069552-63FE3C0E-E8E7-4423-8154-5ED929607197Q30405442-69419A88-3FD2-47D9-8B12-FE42D01572CFQ30971455-A2B7B556-153C-4637-A3BB-6619AB53C3FAQ33833506-7F637899-FC5A-46DE-99CC-89E81A2AAFB6Q34541989-A7B3B9A4-330A-44F1-A180-69EA68779F24Q35093687-79530C8C-BB85-451B-8BE3-FA357F4CE986Q35143875-A758648C-A943-41F9-99CA-DC751313AE3FQ36419013-93071C73-6546-48AB-A2BB-30CCF01740A7Q36478459-33DA9803-CF3A-43D4-9591-3B8C5470EAB2Q36675950-2571207F-09F9-4770-A450-5D50A7DB6738Q36711125-39390131-EA76-4BDA-87F3-085CD19D2AF9Q36983665-B46A3E01-8447-45F1-A7B6-DD6F501EDDF2Q37587294-8EA1B8FE-D70B-4F1E-87D6-7FEF0D704DE4Q37707092-DF16B198-E1A1-48BB-9010-CC5838CC829CQ38398064-63B86B1C-1E8B-40BA-8619-59095ABDC602Q39117246-186983B0-6516-4138-AD50-40F750DE70F4Q39205781-11E89E17-16B1-4EB9-B18A-2C73F3723A26Q39273352-18373850-9F7C-48A4-9FDF-E0CBF40170F8Q39820398-3596F47F-502B-4EEA-9F36-289F277DEA2CQ39841597-B45BA965-16D2-442E-B422-852420676F67Q41625562-1C80EC0B-B3FB-4141-B373-E82299B9E5FFQ42704678-E5EC1753-DA81-4DF1-98F2-7A3E030646C9Q47168387-997FF161-3792-4865-BE1E-D4514251D251Q47942760-3D8E3D3F-CC66-4084-A5B6-9671BD3F3A36
P2860
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@en
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@nl
type
label
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@en
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@nl
prefLabel
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@en
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@nl
P2093
P2860
P1476
Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.
@en
P2093
Kazushi Shigemasa
Keiji Mukai
Koso Ohama
Nobutaka Nagai
Osamu Katoh
Shoji Mihara
Yuko Shiroyama
P2860
P304
P356
10.1111/J.1349-7006.2002.TB01289.X
P577
2002-05-01T00:00:00Z